ASXC - Asensus Surgical, Inc.
NYSE
->
Healthcare
->
Medical Devices
Durham,
United States
Type: Equity
ASXC price evolution
ASXC
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $3.51 | $0.7 | $1.21 | $1.21 |
| Inventory | $7.17 | $6.7 | $9.08 | $8.84 |
| Total current assets | $36.39 | $45.9 | $54.91 | $71.56 |
| Long term investments | ||||
| Property, plant & equipment | $14.12 | $14.2 | $13.7 | $13.74 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $59.09 | $70.7 | $78.37 | $96.52 |
| Current liabilities | ||||
| Accounts payable | $4.14 | $4.5 | $4.28 | $4.97 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $12.63 | $12.1 | $10.65 | $10.88 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $25.67 | $23.5 | $16.87 | $16.81 |
| Shareholders' equity | ||||
| Retained earnings | -$939.37 | -$922.1 | -$903.82 | -$883.15 |
| Other shareholder equity | -$0.61 | -$1.8 | -$1.26 | -$1.53 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $16.36 | |||
| Short term investments | ||||
| Net receivables | $3.51 | $2.81 | $2.06 | $1.11 |
| Inventory | $7.17 | $8.28 | $8.63 | $10.03 |
| Total current assets | $36.39 | $86.87 | $113.3 | $34.01 |
| Long term investments | ||||
| Property, plant & equipment | $14.12 | $14.49 | $16.32 | $10.34 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $44.24 | |||
| Total investments | ||||
| Total assets | $59.09 | $116.05 | $186.47 | $78.26 |
| Current liabilities | ||||
| Accounts payable | $4.14 | $3.35 | $3.45 | $1.97 |
| Deferred revenue | $0.79 | |||
| Short long term debt | ||||
| Total current liabilities | $12.63 | $10.41 | $9.85 | $10.28 |
| Long term debt | $1.59 | |||
| Total noncurrent liabilities | $6.41 | |||
| Total debt | ||||
| Total liabilities | $25.67 | $16.41 | $17.23 | $16.69 |
| Shareholders' equity | ||||
| Retained earnings | -$939.37 | -$860.93 | -$785.37 | -$722.91 |
| Other shareholder equity | -$0.61 | -$2.39 | -$0.26 | $2.97 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.99 | |||
| Cost of revenue | ||||
| Gross Profit | -$1.35 | |||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $17.78 | |||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.09 | |||
| Interest expense | $0.12 | |||
| Net income | ||||
| Net income | -$19.62 | |||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 30 Jan 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3.17 | $8.53 | ||
| Cost of revenue | ||||
| Gross Profit | -$1.99 | -$12.2 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $58.56 | $143.11 | ||
| Operating income | -$60.39 | -$154.57 | ||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$1.52 | -$3.12 | ||
| Interest expense | $0.02 | $4.61 | ||
| Net income | ||||
| Net income | -$59.31 | -$154.2 | ||
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $41.21 | $23.17 | $23.05 | -$119.67 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$0.33 | -$0.33 | -$0.34 | $161.71 |
| Effect of exchange rate | -$0.3 | $0.24 | -$0.04 | $0.38 |
| Change in cash and equivalents | -$4.31 | -$7.15 | $6.73 | $1.76 |
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 31 Jan 2019 |
|---|---|---|---|---|
| Net income | -$59.31 | -$154.2 | ||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$46.67 | -$73.48 | ||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$119.67 | -$0 | $67.64 | -$53.48 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $161.71 | $53.37 | -$5.61 | $26.45 |
| Effect of exchange rate | $0.38 | $0.27 | $0.36 | -$0.43 |
| Change in cash and equivalents | $1.76 | $6.96 | -$11.08 | -$75.95 |
News
|
12 Best Biotech Penny Stocks to Invest In
Insider Monkey via Yahoo Finance
24 Mar 2024
|
|
Asensus Surgical, Inc. (AMEX:ASXC) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance
22 Mar 2024
|
|
Asensus Surgical (ASXC) Completes Surgeon Lab for LUNA
Zacks via Yahoo Finance
8 Jan 2024
|
|
Asensus Surgical, Inc. (AMEX:ASXC) Q3 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance
16 Nov 2023
|
|
Asensus Surgical: Q3 Earnings Snapshot
Washington Post
14 Nov 2023
|
|
Asensus Surgical, Inc. (AMEX:ASXC) Q2 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance
13 Aug 2023
|
|
Asensus Surgical (ASXC) Q2 Loss Widens, Revenues In Line
Zacks via Yahoo Finance
11 Aug 2023
|
|
Asensus Surgical Continues to Spearhead Innovations and Growth in Surgical Robotics
NewMediaWire via Yahoo Finance
6 Aug 2023
|
|
Asensus Shares First Quarter Results and Future Plans
NewMediaWire via Yahoo Finance
1 Jun 2023
|
|
10 Penny Stocks with Insider Buying
Insider Monkey via Yahoo Finance
9 Mar 2023
|
Fundamentals
| Market cap | $66.23M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 264.92M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.88 |
| Quick ratio | 2.31 |